220 related articles for article (PubMed ID: 36789834)
1. Markers of Kidney Tubular Function Deteriorate While Those of Kidney Tubule Health Improve in Primary Aldosteronism After Targeted Treatments.
Wu VC; Chan CK; Chueh JS; Chen YM; Lin YH; Chang CC; Lin PC; Chung SD;
J Am Heart Assoc; 2023 Feb; 12(4):e028146. PubMed ID: 36789834
[TBL] [Abstract][Full Text] [Related]
2. Renal Outcomes in Medically and Surgically Treated Primary Aldosteronism.
Hundemer GL; Curhan GC; Yozamp N; Wang M; Vaidya A
Hypertension; 2018 Sep; 72(3):658-666. PubMed ID: 29987110
[TBL] [Abstract][Full Text] [Related]
3. [Chronic kidney disease after adrenalectomy in a patient with primary aldosteronism].
An WC; Yan HX; Deng ZZ; Chen F; Ou XH; Jin HX; Huang W
Beijing Da Xue Xue Bao Yi Xue Ban; 2021 Dec; 53(6):1201-1204. PubMed ID: 34916706
[TBL] [Abstract][Full Text] [Related]
4. Nonalbuminuric proteinuria as a biomarker for tubular damage in early development of nephropathy with type 2 diabetic patients.
Kim SS; Song SH; Kim IJ; Kim WJ; Jeon YK; Kim BH; Kwak IS; Lee EK; Kim YK
Diabetes Metab Res Rev; 2014 Nov; 30(8):736-41. PubMed ID: 24687388
[TBL] [Abstract][Full Text] [Related]
5. Distinct Dimensions of Kidney Health and Risk of Cardiovascular Disease, Heart Failure, and Mortality.
Lee AK; Katz R; Jotwani V; Garimella PS; Ambrosius WT; Cheung AK; Gren LH; Neyra JA; Punzi H; Raphael KL; Shlipak MG; Ix JH
Hypertension; 2019 Oct; 74(4):872-879. PubMed ID: 31378102
[TBL] [Abstract][Full Text] [Related]
6. NGAL, L-FABP, and KIM-1 in comparison to established markers of renal dysfunction.
Holzscheiter L; Beck C; Rutz S; Manuilova E; Domke I; Guder WG; Hofmann W
Clin Chem Lab Med; 2014 Apr; 52(4):537-46. PubMed ID: 24243749
[TBL] [Abstract][Full Text] [Related]
7. Primary aldosteronism: changes in cystatin C-based kidney filtration, proteinuria, and renal duplex indices with treatment.
Wu VC; Kuo CC; Wang SM; Liu KL; Huang KH; Lin YH; Chu TS; Chang HW; Lin CY; Tsai CT; Lin LY; Chueh SC; Kao TW; Chen YM; Chiang WC; Tsai TJ; Ho YL; Lin SL; Wang WJ; Wu KD;
J Hypertens; 2011 Sep; 29(9):1778-86. PubMed ID: 21738054
[TBL] [Abstract][Full Text] [Related]
8. Plasma kidney injury molecule-1 in heart failure: renal mechanisms and clinical outcome.
Emmens JE; Ter Maaten JM; Matsue Y; Metra M; O'Connor CM; Ponikowski P; Teerlink JR; Cotter G; Davison B; Cleland JG; Givertz MM; Bloomfield DM; Dittrich HC; Todd J; van Veldhuisen DJ; Hillege HL; Damman K; van der Meer P; Voors AA
Eur J Heart Fail; 2016 Jun; 18(6):641-9. PubMed ID: 26511274
[TBL] [Abstract][Full Text] [Related]
9. Predictors of decreasing glomerular filtration rate and prevalence of chronic kidney disease after treatment of primary aldosteronism: renal outcome of 213 cases.
Iwakura Y; Morimoto R; Kudo M; Ono Y; Takase K; Seiji K; Arai Y; Nakamura Y; Sasano H; Ito S; Satoh F
J Clin Endocrinol Metab; 2014 May; 99(5):1593-8. PubMed ID: 24285678
[TBL] [Abstract][Full Text] [Related]
10. Liver fatty-acid-binding protein in heart and kidney allograft recipients in relation to kidney function.
Przybylowski P; Koc-Zorawska E; Malyszko JS; Kozlowska S; Mysliwiec M; Malyszko J
Transplant Proc; 2011 Oct; 43(8):3064-7. PubMed ID: 21996226
[TBL] [Abstract][Full Text] [Related]
11. High urinary excretion of kidney injury molecule-1 is an independent predictor of end-stage renal disease in patients with IgA nephropathy.
Peters HP; Waanders F; Meijer E; van den Brand J; Steenbergen EJ; van Goor H; Wetzels JF
Nephrol Dial Transplant; 2011 Nov; 26(11):3581-8. PubMed ID: 21467131
[TBL] [Abstract][Full Text] [Related]
12. Effects of esaxerenone on blood pressure, urinary albumin excretion, serum levels of NT-proBNP, and quality of life in patients with primary aldosteronism.
Yoshida Y; Fujiwara M; Kinoshita M; Sada K; Miyamoto S; Ozeki Y; Iwamoto M; Mori Y; Nagai S; Matsuda N; Noguchi T; Okamoto M; Gotoh K; Masaki T; Shibata H
Hypertens Res; 2024 Jan; 47(1):157-167. PubMed ID: 37717115
[TBL] [Abstract][Full Text] [Related]
13. Estimated glomerular filtration rate and urine biomarkers in patients with single-ventricle Fontan circulation.
Opotowsky AR; Baraona FR; Mc Causland FR; Loukas B; Landzberg E; Landzberg MJ; Sabbisetti V; Waikar SS
Heart; 2017 Mar; 103(6):434-442. PubMed ID: 27670967
[TBL] [Abstract][Full Text] [Related]
14. Association between plasma aldosterone and markers of tubular and glomerular damage in primary aldosteronism.
Nakamura Y; Kobayashi H; Tanaka S; Hatanaka Y; Fukuda N; Abe M
Clin Endocrinol (Oxf); 2021 Jun; 94(6):920-926. PubMed ID: 33548096
[TBL] [Abstract][Full Text] [Related]
15. Glomerular and tubular damage markers are elevated in patients with diabetes.
Nauta FL; Boertien WE; Bakker SJ; van Goor H; van Oeveren W; de Jong PE; Bilo H; Gansevoort RT
Diabetes Care; 2011 Apr; 34(4):975-81. PubMed ID: 21307379
[TBL] [Abstract][Full Text] [Related]
16. Effects of Intensive Blood Pressure Lowering on Kidney Tubule Injury in CKD: A Longitudinal Subgroup Analysis in SPRINT.
Malhotra R; Craven T; Ambrosius WT; Killeen AA; Haley WE; Cheung AK; Chonchol M; Sarnak M; Parikh CR; Shlipak MG; Ix JH;
Am J Kidney Dis; 2019 Jan; 73(1):21-30. PubMed ID: 30291012
[TBL] [Abstract][Full Text] [Related]
17. Outcomes analysis of surgical and medical treatments for patients with primary aldosteronism.
Park KS; Kim JH; Yang YS; Hong AR; Lee DH; Moon MK; Choi SH; Shin CS; Kim SW; Kim SY
Endocr J; 2017 Jun; 64(6):623-632. PubMed ID: 28458337
[TBL] [Abstract][Full Text] [Related]
18. Tissue expression of tubular injury markers is associated with renal function decline in diabetic nephropathy.
Hwang S; Park J; Kim J; Jang HR; Kwon GY; Huh W; Kim YG; Kim DJ; Oh HY; Lee JE
J Diabetes Complications; 2017 Dec; 31(12):1704-1709. PubMed ID: 29037450
[TBL] [Abstract][Full Text] [Related]
19. Earlier recognition of nephrotoxicity using novel biomarkers of acute kidney injury.
Waring WS; Moonie A
Clin Toxicol (Phila); 2011 Oct; 49(8):720-8. PubMed ID: 21970770
[TBL] [Abstract][Full Text] [Related]
20. Hyperkalemia in both surgically and medically treated patients with primary aldosteronism.
Wada N; Shibayama Y; Umakoshi H; Ichijo T; Fujii Y; Kamemura K; Kai T; Sakamoto R; Ogo A; Matsuda Y; Fukuoka T; Tsuiki M; Suzuki T; Naruse M
J Hum Hypertens; 2017 Oct; 31(10):627-632. PubMed ID: 28540931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
